Detection of Autoantibodies Against Myelin Oligodendrocyte Glycoprotein in Multiple Sclerosis and Related Diseases

  • Melania Spadaro
  • Edgar Meinl
Part of the Methods in Molecular Biology book series (MIMB, volume 1304)


Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) occur in a proportion of patients with different inflammatory demyelinating diseases of the central nervous system, such as childhood multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), and neuromyelitis optica spectrum disorders (NMOSD). We describe here in detail a sensitive cell-based assay that allows the identification of autoantibodies against MOG in serum.


MOG NMOSD MS Demyelination Autoantibody 



This work was supported by the Deutsche Forschungsgemeinschaft (SFB-TR 128; SyNergy), the Klinische Kompetenznetz Multiple Sklerose, Verein zur Therapieforschung für MS Kranke, Werner Reichenberger Stiftung, and Gemeinnützige Hertie Stiftung.


  1. 1.
    Brunner C, Lassmann H, Waehneldt TV et al (1989) Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J Neurochem 52:296–304PubMedCrossRefGoogle Scholar
  2. 2.
    Conrad K, Roggenbuck D, Reinhold D et al (2012) Autoantibody diagnostics in clinical practice. Autoimmun Rev 11:207–211PubMedCrossRefGoogle Scholar
  3. 3.
    Linington C, Bradl M, Lassmann H et al (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130:443–454PubMedCentralPubMedGoogle Scholar
  4. 4.
    Brehm U, Piddlesden SJ, Gardinier MV et al (1999) Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J Neuroimmunol 97:9–15PubMedCrossRefGoogle Scholar
  5. 5.
    Mayer MC, Meinl E (2012) Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord 5:147–159PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    O’Connor KC, McLaughlin KA, De Jager PL et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211–217PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Reindl M, Di Pauli FR, Rostásy K et al (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9:455–461PubMedCrossRefGoogle Scholar
  8. 8.
    Pröbstel AK, Dornmair K, Bittner R et al (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77:580–588PubMedCrossRefGoogle Scholar
  9. 9.
    Mader S, Gredler V, Schanda K et al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273–1277PubMedCrossRefGoogle Scholar
  11. 11.
    Ramanathan S, Reddel SW, Henderson A et al (2014) Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 1:e40. doi: 10.1212/NXI.0000000000000040 PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Titulaer MJ, Hoftberger R, Lizuka T et al (2014) Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 75:411–428PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Spadaro M, Gerdes LA, Mayer MC et al (2015) Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Annal Clin Trans Neurol 3:295–301 doi:10.1002/acn3.164Google Scholar
  14. 14.
    Zhou D, Srivastava R, Nessler S et al (2006) Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 103:19057–19062PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Dale RC, Tantsis EM, Merheb V et al (2014) Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 1:e12. doi: 10.1212/NXI.0000000000000012 PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Saadoun S, Waters P, Owens GP et al (2014) Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2:35. doi: 10.1186/2051-5960-2-35 PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Mayer MC, Breithaupt C, Reindl M et al (2013) Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 191:3594–3604PubMedCrossRefGoogle Scholar
  18. 18.
    Kroepfl F, Viise R, Charron AJ et al (1996) Investigation of myelin/oligodendrocyte glycoprotein membrane topology. J Neurochem 67:2219–2222Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Institute of Clinical Neuroimmunology, Medical Campus GrosshadernLudwig Maximilian UniversityMunichGermany

Personalised recommendations